asgandha

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• ADHD [Insufficient Evidence]
• aging [Insufficient Evidence]
• androgenic alopecia [Insufficient Evidence]
• anxiety [Possibly Effective]
• asthma [Insufficient Evidence]
• athletic performance [Insufficient Evidence]
• back pain [Insufficient Evidence]
• bipolar disorder [Insufficient Evidence]
• bronchitis [Insufficient Evidence]
• cerebellar ataxia [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• cognitive impairment [Insufficient Evidence]
• constipation [Insufficient Evidence]
• COPD [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• depression [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• fatigue [Insufficient Evidence]
• fatigue, chemo-related [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• generalized anxiety disorder [Possibly Effective]
• hiccups [Insufficient Evidence]
• hypercholesterolemia [Insufficient Evidence]
• hypothyroidism [Insufficient Evidence]
• infertility in patients of childbearing potential [Insufficient Evidence]
• insomnia [Possibly Effective]
• lichen planus [Insufficient Evidence]
• male infertility [Insufficient Evidence]
• menopausal symptoms [Insufficient Evidence]
• metabolic effects, antipsychotic-induced [Insufficient Evidence]
• obsessive-compulsive disorder [Insufficient Evidence]
• osteoarthritis [Insufficient Evidence]
• Parkinson disease [Insufficient Evidence]
• psychological well-being [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• sexual dysfunction [Insufficient Evidence]
• smoking cessation [Insufficient Evidence]
• stress [Possibly Effective]
• tuberculosis [Insufficient Evidence]
• vitiligo [Insufficient Evidence]
• wound healing [Insufficient Evidence]
• wrinkled skin [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

aging

[Insufficient Evidence]

Dose: 600 mg PO qd

androgenic alopecia

[Insufficient Evidence]

Dose: apply 1-2 drops serum topically qd; Info: product containing 5% root extract

anxiety

[Possibly Effective]

Dose: 0.3 g PO bid; Alt: 0.5-12 g PO qd

athletic performance

[Insufficient Evidence]

Dose: 500-1000 mg PO qd; Alt: 120-1250 mg/day PO divided qd-bid

bipolar disorder

[Insufficient Evidence]

Dose: 250 mg PO bid; Start: 250 mg PO qd x1wk

cerebellar ataxia

[Insufficient Evidence]

Dose: 500 mg PO tid

cognitive impairment

[Insufficient Evidence]

Dose: 250 mg PO qd

constipation

[Insufficient Evidence]

Dose: 300-500 mg PO qd; Info: product containing 45% extract in 1:1 ratio ashwagandha root:ambrette fruit

COPD

[Insufficient Evidence]

Dose: 250 mg PO bid; Info: used with conventional tx

COVID-19

[Insufficient Evidence]

Dose: 500-600 mg PO bid

depression

[Insufficient Evidence]

Dose: 500 mg PO qd

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 3 g PO qd

fatigue

[Insufficient Evidence]

Dose: 200 mg PO bid

fatigue, chemo-related

[Insufficient Evidence]

Dose: 2 g PO tid

generalized anxiety disorder

[Possibly Effective]

Dose: 0.06-1 g PO qd; Alt: 4 g PO tid; Info: used with or without standard tx

hypercholesterolemia

[Insufficient Evidence]

Dose: 3 g PO qd

hypothyroidism

[Insufficient Evidence]

Dose: 300 mg PO bid

insomnia

[Possibly Effective]

Dose: 120-600 mg PO qd

lichen planus

[Insufficient Evidence]

Dose: apply topically bid; Info: for patients with oral lichen planus with gingival presentation

male infertility

[Insufficient Evidence]

Dose: 5 g PO qd; Alt: 225 mg PO tid

menopausal symptoms

[Insufficient Evidence]

Dose: 300 mg PO bid

metabolic effects, antipsychotic-induced

[Insufficient Evidence]

Dose: 400 mg PO tid

obsessive-compulsive disorder

[Insufficient Evidence]

Dose: 120 mg PO qd; Start: 30 mg PO qd x4 days, then incr. by 30 mg/day q4 days; Info: used with selective-serotonin reuptake inhibitor

osteoarthritis

[Insufficient Evidence]

Dose: 900 mg PO tid

Parkinson disease

[Insufficient Evidence]

Dose: 14.5 g PO bid

psychological well-being

[Insufficient Evidence]

Dose: 350 mg PO bid

rheumatoid arthritis

[Insufficient Evidence]

Dose: 5 g PO bid

sexual dysfunction

[Insufficient Evidence]

Dose: 300 mg PO bid

smoking cessation

[Insufficient Evidence]

Dose: 100 mg PO qd

stress

[Possibly Effective]

Dose: 240-1000 mg PO qd; Alt: 300-500 mg PO bid

wrinkled skin

[Insufficient Evidence]

Dose: apply 8% lotion topically qd